Vimian Group AB (publ) (VIMGF)

Market Cap	1.53B -18.4%
Revenue (ttm)	499.12M +13.4%
Net Income	36.75M +69.2%
EPS	0.07 +62.1%
Shares Out	n/a
PE Ratio	41.51
Forward PE	21.39
Dividend	n/a
Ex-Dividend Date	n/a

Volume	569
Average Volume	6,629
Open	2.770
Previous Close	3.010
Day's Range	2.770 - 2.770
52-Week Range	2.770 - 4.500
Beta	1.40
RSI	40.98
Earnings Date	Mar 19, 2026

About Vimian Group AB

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 1,033
• Stock Exchange: OTCMKTS
• Ticker Symbol: VIMGF

Financial Performance

In 2025, Vimian Group AB's revenue was 425.10 million, an increase of 13.42% compared to the previous year's 374.80 million. Earnings were 31.30 million, an increase of 69.19%.

Financial numbers in EUR